USA – Foresite Capital, a San Francisco, CA-based multi-stage healthcare and life sciences investment firm, raised a $173 million fund.
The vehicle will further invest in companies launched by Foresite Labs incubator program to help them scale and solve the biggest unmet needs in healthcare. Foresite Labs companies will also continue to be supported from Foresite Capital Fund V and its associated opportunities fund. The fund follows several major milestones for Foresite Capital including the announcement of its $969m Fund V and investments in Foresite Labs incubated companies Interline Therapeutics, Alumis and TenSixteen Bio.Foresite Labs was created in October 2019 to found, build and scale life sciences companies at the intersection of healthcare and data science. The Foresite Labs team is led by Foresite Capital managing director Dr. Vikram Bajaj, CEO, who is the former chief scientific officer of GRAIL and was the co-founder and chief scientific officer of Verily (formerly Google Life Sciences). The firm utilizes its data science platform to launch and support next-generation therapeutics and healthcare services companies to ultimately improve patient outcomes. Foresite Labs has announced the launch of five companies, and is incubating several additional concepts.Led by Jim Tananbaum, founder and CEO, Foresite Capital is a multi-stage healthcare and life sciences investment firm with approximately $4 billion in assets under management. The firm aims to address areas of great unmet need by funding promising healthcare and life sciences businesses at all stages of their life cycles. Foresite Capital uses a data science-driven approach to invest in companies that leverage biology and big data to transform healthcare. Founded in 2011, Foresite Capital is based in the San Francisco Bay Area and New York City. 04/03/2022
